These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

198 related items for PubMed ID: 9261533

  • 1. Short-course intravenous prophylaxis for paclitaxel-related hypersensitivity reactions.
    Bookman MA, Kloth DD, Kover PE, Smolinski S, Ozols RF.
    Ann Oncol; 1997 Jun; 8(6):611-4. PubMed ID: 9261533
    [Abstract] [Full Text] [Related]

  • 2.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 3. An effective and more convenient drug regimen for prophylaxis against paclitaxel-associated hypersensitivity reactions.
    Markman M, Kennedy A, Webster K, Peterson G, Kulp B, Belinson J.
    J Cancer Res Clin Oncol; 1999 Jul; 125(7):427-9. PubMed ID: 10394964
    [Abstract] [Full Text] [Related]

  • 4. Paclitaxel premedication regimens.
    Boehm DK, Maksymiuk AW.
    J Natl Cancer Inst; 1996 Apr 03; 88(7):463-5. PubMed ID: 8618242
    [No Abstract] [Full Text] [Related]

  • 5. A comparison of two prophylactic regimens for hypersensitivity reactions to paclitaxel.
    Kwon JS, Elit L, Finn M, Hirte H, Mazurka J, Moens F, Trim K.
    Gynecol Oncol; 2002 Mar 03; 84(3):420-5. PubMed ID: 11855881
    [Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9. Intravenous prophylaxis for paclitaxel-related hypersensitivity reactions.
    Bookman MA, Kloth DD, Kover PE, Smolinski S, Ozols RF.
    Semin Oncol; 1997 Dec 03; 24(6 Suppl 19):S19-13-S19-15. PubMed ID: 9427258
    [Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18. Paclitaxel-associated hypersensitivity reactions: experience of the gynecologic oncology program of the Cleveland Clinic Cancer Center.
    Markman M, Kennedy A, Webster K, Kulp B, Peterson G, Belinson J.
    J Clin Oncol; 2000 Jan 03; 18(1):102-5. PubMed ID: 10623699
    [Abstract] [Full Text] [Related]

  • 19. Phase II trial of paclitaxel by three-hour infusion for advanced gastric cancer with short premedication for prophylaxis against paclitaxel-associated hypersensitivity reactions.
    Yamada Y, Shirao K, Ohtsu A, Boku N, Hyodo I, Saitoh H, Miyata Y, Taguchi T.
    Ann Oncol; 2001 Aug 03; 12(8):1133-7. PubMed ID: 11583196
    [Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 10.